ALZN vs. CYCC, PTPI, XCUR, ENSC, SNGX, THAR, CLVR, GTBP, SEEL, and ZVSA
Should you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Cyclacel Pharmaceuticals (CYCC), Petros Pharmaceuticals (PTPI), Exicure (XCUR), Ensysce Biosciences (ENSC), Soligenix (SNGX), Tharimmune (THAR), Clever Leaves (CLVR), GT Biopharma (GTBP), Seelos Therapeutics (SEEL), and ZyVersa Therapeutics (ZVSA). These companies are all part of the "pharmaceutical preparations" industry.
Alzamend Neuro (NASDAQ:ALZN) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.
In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than Alzamend Neuro. MarketBeat recorded 3 mentions for Cyclacel Pharmaceuticals and 0 mentions for Alzamend Neuro. Cyclacel Pharmaceuticals' average media sentiment score of 1.52 beat Alzamend Neuro's score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.
Cyclacel Pharmaceuticals received 183 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 49.08% of users gave Cyclacel Pharmaceuticals an outperform vote.
Cyclacel Pharmaceuticals has a consensus price target of $11.00, suggesting a potential upside of 404.59%. Given Cyclacel Pharmaceuticals' higher probable upside, analysts plainly believe Cyclacel Pharmaceuticals is more favorable than Alzamend Neuro.
49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 52.2% of Alzamend Neuro shares are owned by insiders. Comparatively, 8.0% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Alzamend Neuro has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
Alzamend Neuro has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -4,401.34%. Alzamend Neuro's return on equity of -612.26% beat Cyclacel Pharmaceuticals' return on equity.
Alzamend Neuro has higher earnings, but lower revenue than Cyclacel Pharmaceuticals. Alzamend Neuro is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Cyclacel Pharmaceuticals beats Alzamend Neuro on 9 of the 16 factors compared between the two stocks.
Get Alzamend Neuro News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alzamend Neuro Competitors List
Related Companies and Tools
